

ΩTB[®] Genome Analysis Report

Sample Summary						
Sample ID	#######	Client ID	##########	Test ID	##########	
Sample Type	gDNA	Sample Receipt Date	ddmmyyyy	Sample Temperature on Receipt	Xyz ⁰ C	
Sample Source	Culture	Sample QC Date	ddmmyyyy	Sample QC	260/280 = 1.8 Concentration = 28 ng/µl	

Genome Sequencing Summary						
Library Type	Whole Genome. PE x 150	Library Date	ddmmyyyy	Library QC	Good (4nm)	
Genome Sequencer	Illumina NextSeq 500	Run Date	ddmmyyy	Machine ID Lane ID	########### \$\$\$\$\$\$\$\$\$\$\$\$\$\$	

Genomic Analysis Application Summary							
Application	ΩTB <i>ver</i> 2.0.1	Run Date	ddmmyyyy	QC check	Pass	Application Run By	

Clinical summary

Mycobacterium	Yes	Coverage	0.99
tuberculosis detected			
Lineage	Beijing	% of genome covered	99.24

Drug susceptibility profile

Antibiotic	Presence of Drug-Resistant Mutation
Rifampicin (RMP)	Detected
Isoniazid (INH)	Detected
Ethambutol (EMB)	Detected
Pyrazinamide (PZA)	Detected
Streptomycin (SM)	Detected
Capreomycin (CAP)	Detected
Kanamycin (KAN)	Detected
Amikacin (AMK)	Detected
Moxifloxacin (MOX)	Detected
Ofloxacin (OFX)	Detected
Gatifloxacin (GAT)	Detected
Ethionamide (ETO)	Not Detected
Linezolid (LZD)	Not Detected
Para-aminosalicylic acid (PAS)	Not Detected
Bedaquiline (BDQ)	Not Detected
Clofazimine (CLO)	Not Detected
Delamanid (DMD)	Not Detected
Pretomanid (PTM)	Not Detected


Clinical Recommendation

- Tuberculosis antibiotic profile: Extremely Drug Resistant Tuberculosis (XDR-TB)a
- Mixed infection: Heterozygous calls detected
- Other pathogens: NA



ΩTB® Genome Analysis Report

Antibiogram



RIF: Rifampicin, INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, STR: Streptomycin, CAP: Capreomycin, KAN: Kanamycin, AMK: Amikacin, MOX: Moxifloxacin, OFX: Ofloxacin, GAT: Gatifloxacin, ETO: Ethionamide, LZD: Linezolid, PAS: Para-aminosalicylic acid, BDQ: Bedaquiline, CLO: Clofazimine, DMD: Delamanid





Not Drug Resistant

ΩTB[®] Genome Analysis Report

List of variants used to call resistance

Position	Ref allele	Alternate allele	Туре	Frequency	Coverage	Substitution	Gene Symbol	Gene Name	Drug	Pubmed ID	Mutation Confidence
781687	А	G	SNP	99.17	113	Lys43Arg (aag/aGg)	Rv0682	rpsL	SM	22646308	Yes
761155	С	Т	SNP	100.00	51	Ser450Leu (tcg/tTg)	Rv0667	rpoB	RMP	7759399	Yes
2288847	С	G	SNP	100.00	44	Gly132Ala (ggt/gCt)	Rv2043c	pncA	PZA	25336456	Yes
155168	С	G	SNP	100.00	81	Ser315Thr (agc/aCc)	Rv1908c	katG	INH	8878604	Yes
7564	G	С	SNP	100.00	42	Gly88Ala (ggc/gCc)	Rv0006	gyrA	FQ	24055765	Yes
7570	С	Т	SNP	98.90	48	Ala90Val (gcg/gTg)	Rv0006	gyrA	FQ	21300839	Yes
247429	Α	G	SNP	100.00	102	Met306Val (atg/Gtg)	Rv3795	embB	EMB	21300839	Yes
1473246	Α	G	SNP	97.60	49	-	Rvnr01		AMK,KAN,CAP	21300839	Yes

Mutation confidence: Confidence of mutation for calling drug resistance as per WHO guidelines
Pubmed ID: Identification of peer reviewed study demonstrating mutation associated with drug resistance

ΩΤΒ	Drug resistance classification criteria		
Multidrug resistant tuberculosis	Tuberculosis caused by Mycobacterium tuberculosis strains that is resistance		
(MDR-TB)	to at least Isoniazid and Rifampicin.		
Pre-extensively drug-resistant	Tuberculosis caused by Mycobacterium tuberculosis strains that fulfil the		
tuberculosis (Pre-XDR-TB)	definition of MDR/Rifampicin Resistant-TB and that are also resistant to any		
	Fluoroquinolones		
Extensively drug-resistant	Tuberculosis caused by Mycobacterium tuberculosis strains that fulfil the		
tuberculosis (XDR-TB)	definition of MDR/Rifampicin Resistant-TB and that are also resistant to any		
	Fluoroquinolones and at least one additional Group A drug (The Group A drugs		
	are currently Levofloxacin or Moxifloxacin, Bedaquiline and Linezolid)		
Drug resistance detected	Tuberculosis caused by Mycobacterium tuberculosis (M. tuberculosis) strains		
	that is resistant to anti-TB drugs and do not fall in the above-mentioned		

	Mixed infection classification criteria
	Wilked Illiection classification criteria
>25% showing heterozygous calls	
2070 Griowing Hotorozygodo Galle	

No resistance to the anti-TB drugs detected

categories

Co-infection classification criteria				
>20% coverage of	genome mapping to co-infected pathogen			



ΩTB[®] Genome Analysis Report



© HaystackAnalytics Pvt. Ltd. 2021 For use by a registered medical practitioner or hospital only